Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Developmental therapeutics / investigational immunotherapy

1926 - Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors.


20 Oct 2018


Poster Discussion session - Developmental therapeutics / investigational immunotherapy


Clinical Research;  Immunotherapy;  Translational Research

Tumour Site


Jacques Medioni


Annals of Oncology (2018) 29 (suppl_8): viii133-viii148. 10.1093/annonc/mdy279


J. Medioni1, M. Brizard2, L.O. Teixeira3, L. Doucet4, Z. Ghrieb5, A. Angelergues4, S. Oudard6, S. Culine7, O. Adotevi8, C. Laheurte8, M. Dragon-Durey9, P. Laurent-Puig10, J. Kiladjian3, V. Doppler11, B. Souttou12, S. Wain-Hobson12, R. Defrance12, T. Huet11, P. Langlade-Demoyen12

Author affiliations

  • 1 Medical Oncology Department, Hôpital Européen Georges Pompidou, 75015 - Paris/FR
  • 2 Service D'oncologie Medicale, Hôpital Européen Georges Pompidou, 75015 - Paris/FR
  • 3 Centre D'investigations Cliniques, Hôpital St. Louis, 75010 - Paris/FR
  • 4 Oncologie Médicale, Hôpital St. Louis, 75010 - Paris/FR
  • 5 Centre D’investigations Cliniques, Hôpital St. Louis, 75010 - Paris/FR
  • 6 Immunothérapie Et Traitement Antiangiogénique En Pathologie cancérologique, Hopital European George Pompidou, 75015 - Paris/FR
  • 7 Medical Oncology, Hôpital St. Louis, 75010 - Paris/FR
  • 8 Immunomolecular Therapy Of Cancer, UMR1098, 25020 - Besançon/FR
  • 9 Laboratoire D’immunobiologie, Hôpital Européen Georges Pompidou, 75015 - Paris/FR
  • 10 Umr-s 1147, Université Paris-Descartes, 75010 - Paris/FR
  • 11 Clinical Development, Invectys, 75 - Paris/FR
  • 12 Clinical Development, Invectys, 75014 - Paris/FR

Abstract 1926


INVAC-1 is an optimized plasmid encoding an inactive form of hTERT, a tumor antigen expressed in most of human tumors with little or no expression in normal somatic cells. We report here clinical response and pharmacodynamics of INVAC-1.


A two center Phase I trial evaluated INVAC-1 given monthly for 3 cycles using intra-dermal injection followed by electroporation. Immune monitoring comprised detection of autoantibodies, lymphocyte phenotyping, inflammatory cytokine levels in blood, and CD4 and CD8 anti-hTERT responses assessed by Elispot IFN-γ. Anti-tumor activity was evaluated through RECIST 1.1 adapted to immune response, and plasma ctDNA.


Twenty patients (pts) with refractory/progressive tumors were enrolled and treated at three escalating doses of 100 µg, 400 µg and 800 µg. 12 pts experienced stable disease according to RECIST. For 10 of them, the treatment was extended up to nine months. INVAC-1 was well tolerated with no dose-limiting toxicities. No significant biological signs of autoimmunity were observed. A majority of pts had high levels of inflammatory plasma cytokines at inclusion but no significant modification was observed after INVAC-1 administration. IFN-γ polarized anti-hTERT CD4/CD8 immune responses were detected in 55% of pts, following INVAC-1 injections. INVAC-1 triggered de novo antihTERT response or enhanced pre-existing natural anti-hTERT immunity. The majority of pts mounted anti-hTERT T cell responses following the second- or third vaccination. ctDNA was evaluated in 14 pts. The most frequent mutations were TP53, KRAS and PIK3CA. We observed a ctDNA decrease in 5 cases, a stable ctDNA level in 5 cases and an increase in 4 cases.


Results indicate that INVAC-1 was well tolerated and immunogenic at the doses and schedule tested. Disease stabilization was obtained for the majority of pts, according to RECIST criteria or ctDNA levels. Phase II studies of INVAC-1 in solid tumors and hematologic malignancies, preferably in pts with early diseases and adequate immune functions, are starting.

Clinical trial identification


Legal entity responsible for the study




Editorial Acknowledgement


J. Medioni, L.O. Teixeira, L. Doucet, S. Oudard, S. Culine, O. Adotevi, M.-A. Dragon-Durey, P. Laurent-Puig: Study investigator. V. Doppler: Sponsor employee. B. Souttou: Sponsor employer. S. Wain-Hobson: Invectys co-founder. R. Defrance: Consultant for study sponsor. T. Huet: Sponsor employee. P. Langlade-Demoyen: Invectys co-founder and CEO. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.